Avid Bioservices Inc (CDMO)

[biopharm]

CP, I would assume SEC and other bodies would have seen those correlations and I guess it is good if all sent in all info related on that post re: Avid CDMO stock manipulation

NASDAQ just updated their site yesterday and actually, rather poorly as it was easier to see ALL IIS invested in CDMO quickly and without confusion ...unless they did it to not make it as easily noticeable for the general public?

Next, the exosomes technology is also being used it looks like with BIA Separations with the help of ex VP Process Science at Avid = Peter Gagnon

His welcome at BIA hid the fact he was with Avid Bioservices and there is much more ...

________

BIA Separations Introduces Cornerstone AAV Process Development Service to Accelerate Gene Therapy Production

CORNERSTONE program integrates process development expertise and novel technology to remove development bottlenecks in the manufacture of Gene Therapy Medicinal Products (GTMPs)

By BIA Separations | September 11, 2019

...
...
...

"The cornerstone of any new construction project defines it future," said Pete Gagnon, chief scientific officer at BIA Separations. "This is the principle behind our process development program, and we look forward to it becoming the cornerstone of many clinical successes. Over the coming months, we will introduce additional tools and procedures to help scientists meet the unique challenges they face with bringing new therapeutic classes to clinical trials, and eventually to commercial production. Starting with AAVs, the program will expand to include other viral vectors, exosomes, mRNA, and DNA plasmids, among other emerging prospects."

â??The launch of our CORNERSTONE program reflects BIA Separationsâ?? transition from a product supplier to a full-service solutions company for gene therapy," added Ingo Nagler, business development officer at BIA Separations. "We have the requisite experience and know-how, alongside real breakthrough technologies that have potential to significantly accelerate the pace of gene therapy programs for our clients. Our new service responds to an urgent need in the biopharmaceutical industry for turn-key gene therapy production processes, and we believe we are ideally placed to deliver these.â?
...
....
....

https://www.google.com/amp/s/www.labmanager.com/news/2019/09/bia-separations-introduces-cornerstone-aav-process-development-service-to-accelerate-gene-therapy-production/amp

______________

Peter Gagnon VP Avid Bioservices ...now in Austria with BIA Separations ( our ex Eric Swartz quite familiar with Austria ) and why are all court records sealed up on everything ??

All Peter Gagnon latest patents belong to "AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH" in Singapore

https://patents.justia.com/inventor/peter-gagnon

https://www.a-star.edu.sg/

Why the hell would John Springs Stafford be part of shifting the IP over to Oncologie Inc when the money backers are now being tied to IP assets that have HELPED secure other patents that required the knowledge of PS Targeting IP?

______________

Avid Bioservices Appoints Pete Gagnon as Vice President of Process Sciences

Leading Innovator in Field of Biologics Purification Brings Unique Manufacturing Experience to Broaden Avid's Capabilities, Including Biosimilar Expertise

May 23, 2016

https://www.globenewswire.com/news-release/2016/05/23/1080008/0/en/Avid-Bioservices-Appoints-Pete-Gagnon-as-Vice-President-of-Process-Sciences.html


______________


BIA Separations appoints Pete Gagnon as Chief Scientific Officer

Jan 7, 2018

BIA Separations (BIA), a leading biochromatography development and manufacturing company, today announced it has appointed Pete Gagnon as Chief Scientific Officer. In his new role, he will drive the company's new product and applications development, with a focus on the purification of products for gene therapy, oncolytic vaccines, exosomes and similar, and specifically increasing the safety of these products.

Previously President and CSO of Validated Biosystems, Gagnon assumes his new position with immediate effect. Gagnon has more than 30 years of experience in the biotech industry where he is widely respected for his work in the development of purification technology for the manufacture of biologics, including viruses and exosomes. The majority of his experience has been gained in the development of commercial purification procedures for recombinant human therapeutics. During his career, he has worked with all major chromatography suppliers, supporting the development of new products and applications in line with rapidly evolving industry needs.

Gagnon is the inventor of 20 granted patent families with 20 more pending, and has published more than 80 articles, cited in more than 700 scientific publications, addressing practical aspects of purifying biologics. He has authored a book titled Purification Tools for Monoclonal Antibodies, as well as being invited to contribute chapters to many other books, and sits on numerous scientific and editorial advisory boards.

Aleš Štrancar, CEO of BIA Separations, commented: "Pete's scientific interests and experience are a perfect fit with our future development strategy and the stringent requirements associated with these classes of products. He has been an influential researcher and a user of BIAs proprietary CIM® monolith technology for more than a decade, and his enthusiasm, practical skills and insights will make him an invaluable resource for our customers and partners, especially in the fast-developing and challenging fields of virus and exosome purification. This is an area where we expect to see new product lines emerging."

Pete Gagnon, CSO of BIA Separations added: "I am sincerely delighted to join BIA where I look forward to highlighting the unique abilities of monoliths to elevate product quality, safety, and processing efficiency for some of the most challenging product classes in the field of human therapeutics. Process developers should anticipate the emergence of important and exciting first-in-the-field capabilities by mid-year, and continuing thereafter."

Pete Gagnon, CSO of BIA Separations

Media contact:
Sarah Jeffery
Zyme Communications
E: [e-mail]
T: [phone]

_______


So his patents now heading to Singapore and what knowledge learned at Avid - PS Targeting did he pick up? This Fung may be tied to Nan Fung ...

Ms Chan Lai Fung
Chairman
Agency for Science, Technology and Research

Ms Chan Lai Fung is the Chairman of A*STAR. She was appointed to her current position on 1 April 2019 and assumes the responsibility for charting A*STAR’s strategic direction and priorities under the national Research, Innovation and Enterprise (RIE) plan.

Ms Chan is also currently Permanent Secretary (National Research & Development).

Prior to that, Ms Chan was Permanent Secretary (Education) from 2012 to 2019. She was appointed Permanent Secretary (Finance) (Performance) from 2009 to 2012; and Permanent Secretary (Law) from 2006 to 2010. She has also served in various portfolios in the former Ministry of Communications and Information, Ministry of Health, Ministry of Finance, Public Service Division of the Prime Minister’s Office, Ministry of the Environment and Ministry of Trade and Industry.

Ms Chan is a board member of PSA International Pte Ltd.

Ms Chan joined the Singapore Administrative Service in 1986 after graduating from Monash University in Australia with a Bachelor of Economics (First Class Honours) on a Colombo Plan Scholarship.

https://www.a-star.edu.sg/About-A-STAR/Corporate-Profile/A-STAR-Board/Ms-Chan-Lai-Fung

_________

BIA Separations with ties to JSR Corp starting in 2011 and Scott Antonia patents were bought out by KBI ...bought further up by JSR ...like no one notices??!!

The undisclosed investor of KBI holds more info to this cover up trying to hold back PS Targeting IP

KBI buyout investor = undisclosed

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=138425089